Oral Semaglutide: A New GLP-1 Receptor Agonist Product for the Treatment of Type 2 Diabetes

1. In addition to being recommended in patients with a history of atherosclerotic cardiovascular disease (ASCVD), glucagon-like peptide-1 (GLP-1) receptor agonists are recommended for consideration as an add-on to metformin in patients without established ASCVD in whom there is a compelling need to do which of the following?
2. Which of the following is not a mechanism of glucose lowering for GLP-1 receptor agonists?
3. Which of the following GLP-1 receptor-agonist products is considered to be short-acting?
4. Which of the following is a major factor that has led to poor oral absorption of GLP-1 receptor agonists in the past?
5. Where is oral semaglutide absorbed?
6. Which of the following is not a mechanism by which sodium N-[8 (2-hydroxylbenzoyl) amino] caprylate (SNAC) acts to facilitate oral semaglutide absorption?
7. Which of the following statements is true based on manufacturer recommen-dations for use of oral semaglutide?
8. Which PIONEER study showed that oral semaglutide was noninferior to placebo in terms of cardiovascular risk?
9. Oral semaglutide should not be taken together with which medication due to a potential for a serious drug-drug interaction?
10. What are the most common adverse events associated with oral semaglutide use?
Evaluation Questions
11. Met objective 1:
12. Met objective 2:
13. Met objective 3:
14. Met objective 4:
15. Related to your educational needs:
16. The active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
17. Avoided commercial bias:
18. How would you rate the overall usefulness of the material presented?
19. How would you rate the quality of the faculty?
20. How would you rate the appropriateness of the examination for this activity?